SCHEMBL3356308

SCHEMBL3356308

Nc1ccc2nc(-c3ccnnc3)cn2n1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE10A Q9Y233 1/20 0.38
DYRK1A Q13627 2/20 0.37
NPC1 O15118 3/20 0.35
RAB9A P51151 3/20 0.35
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
TP53 P04637 1/20 0.33
PIK3CG P48736 4/20 0.33
PIK3CA P42336 3/20 0.33
PIK3CD O00329 3/20 0.33
PIK3CB P42338 2/20 0.33
CSNK1D P48730 3/20 0.32
CSNK1E P49674 3/20 0.32
FGFR1 P11362 2/20 0.31
ATR Q13535 1/20 0.31
NTRK1 P04629 1/20 0.31
IGF1R P08069 1/20 0.31
LTK P29376 1/20 0.31
MAP2K2 P36507 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3357413 0.76 NPC1 (0.36) PDE10ADYRK1ANPC1RAB9AMEN1
SCHEMBL2536912 0.75 RAB9A (0.48) PDE10ANPC1RAB9AMEN1KMT2A
SCHEMBL16009643 0.72 CYP1A2 (0.47) DYRK1ANPC1RAB9ASMN1; SMN2PIK3CG
SCHEMBL18613326 0.72 ALDH1A3 (0.56) DYRK1ANPC1RAB9AMEN1KMT2A
SCHEMBL10284772 0.72 APP (0.47) DYRK1ANPC1RAB9AMEN1KMT2A
SCHEMBL2540334 0.70 APP (0.42) DYRK1ANPC1RAB9AMEN1KMT2A
SCHEMBL5306486 0.68 APP (0.38) DYRK1ANPC1RAB9AMEN1KMT2A
SCHEMBL13579042 0.68 KDM4E (0.51) PDE10ANPC1RAB9AMEN1KMT2A
SCHEMBL3359311 0.68 FYN (0.47) DYRK1A
SCHEMBL15382662 0.67 ADORA2A (0.52) MEN1KMT2AKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9108971-B2 6-cycloamino-3-(pyridazin-4-yl)imidazo[1,2-b]-pyridazine and derivatives thereof preparation and therapeutic application thereof SANOFI (FR) 2015-08-18 US disclosed
US-20130245023-A1 6-CYCLOAMINO-3-(PYRIDAZIN-4-YL)IMIDAZO[1,2-b]-PYRIDAZINE AND DERIVATIVES THEREOF PREPARATION AND THERAPEUTIC APPLICATION THEREOF SANOFI (FR) 2013-09-19 US disclosed
EP-2178879-B1 6-CYCLOAMINO-S-(PYRIDAZIN-4-YL)IMIDAZO[1,2-B]-PYRIDAZINE AND DERIVATIVES THEREOF PREPARATION AND THERAPEUTIC APPLICATION THEREOF SANOFI SA (FR) 2013-07-03 EP disclosed
US-8455491-B2 6-cycloamino-3-(pyridazin-4-yl)imidazo[1,2-b]pyridazine and derivatives and pharmaceutical compositions comprising the same SANOFI (FR) 2013-06-04 US disclosed
US-20100152157-A1 6-CYCLOAMINO-3-(PYRIDAZIN-4-YL)IMIDAZO[1,2-b]-PYRIDAZINE AND DERIVATIVES THEREOF PREPARATION AND THERAPEUTIC APPLICATION THEREOF SANOFI-AVENTIS (FR) 2010-06-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130245023-A1 6-CYCLOAMINO-3-(PYRIDAZIN-4-YL)IMIDAZO[1,2-b]-PYRIDAZINE AND DERIVATIVES THEREOF PREPARATION AND THERAPEUTIC APPLICATION THEREOF TLR7, IFNAR1, CBR3 PDE10A 1714/4885DYRK1A 2639/4885NPC1 3017/4885
US-20100152157-A1 6-CYCLOAMINO-3-(PYRIDAZIN-4-YL)IMIDAZO[1,2-b]-PYRIDAZINE AND DERIVATIVES THEREOF PREPARATION AND THERAPEUTIC APPLICATION THEREOF IFNAR1, TLR7, CBR3 PDE10A 1719/4885DYRK1A 2644/4885NPC1 3082/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.